NeuroMetrix, Inc. (NASDAQ:NURO) Sees Significant Decrease in Short Interest

NeuroMetrix, Inc. (NASDAQ:NURO) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 31,100 shares, a decline of 26.7% from the November 15th total of 42,400 shares. Based on an average trading volume of 17,600 shares, the days-to-cover ratio is currently 1.8 days. Currently, 2.1% of the shares of the stock are sold short.

NeuroMetrix Trading Down 2.3 %

NURO stock traded down $0.09 during trading on Friday, hitting $3.81. The company had a trading volume of 6,006 shares, compared to its average volume of 24,678. The company has a fifty day moving average price of $4.09 and a two-hundred day moving average price of $3.84. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73. The company has a market cap of $7.77 million, a P/E ratio of -0.85 and a beta of 2.18.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. The company had revenue of $0.59 million for the quarter. During the same period in the previous year, the firm posted ($1.66) earnings per share.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of NeuroMetrix in a research note on Friday, December 6th. They set a “sell” rating for the company.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.